MASS$5.515
Chart
Performance
Key Stats
AI MASS Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
Buy908 Devices Inc. shows mixed signals. While fundamental metrics indicate a company with significant revenue growth and a strong balance sheet, profitability remains a concern with consistent net losses. Thematic alignment is positive, but technical indicators suggest short-term volatility. Investors should consider a long-term perspective and acknowledge the current unprofitability.
Thematic
908 Devices Inc. operates in the life sciences and bioprocessing sectors, which are driven by strong thematic trends in technological advancement in healthcare, drug discovery, and biomanufacturing. The company's mass spectrometry devices cater to critical analytical needs in these expanding markets.
Fundamental
908 Devices Inc. demonstrates strong revenue growth, indicating increasing market acceptance of its products. However, persistent net losses and high operating expenses are significant concerns. The balance sheet is relatively healthy with substantial cash reserves, but the company's path to profitability needs to be closely monitored.
Technical
908 Devices Inc. is trading within its 52-week range, showing some upward momentum but also facing resistance. Technical indicators are mixed, with some suggesting potential buying opportunities and others indicating caution due to overbought conditions on shorter timeframes.
| Factor | Score |
|---|---|
| Life Sciences & Biotechnology Advancement | 90 |
| Precision Medicine & Diagnostics | 85 |
| Bioprocessing & Manufacturing Efficiency | 80 |
| Forensics & Safety Applications | 70 |
| Market Adoption & Competition | 75 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 20 |
| Growth | 80 |
| Balance Sheet Health | 85 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 60 |
| Momentum | 65 |
| Volume Confirmation | 55 |
| Support & Resistance | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Earnings Surprise
Reported EPS of $1.23 in Q2 2025 significantly exceeded the estimate of $-0.32, indicating strong operational performance and better-than-expected profitability.
Exceptional Short-Term Growth
The stock has shown remarkable growth, with a 6-month performance of 200.4% and Year-to-Date (YTD) performance of 238.81%, suggesting strong positive momentum and investor interest.
Bearish Points (8)
Inconsistent EPS Performance
While Q2 2025 saw a significant EPS beat, Q1 2025 reported an EPS of $-0.56 against an estimate of $-0.35, a substantial miss (-61.85%), highlighting earnings volatility.
Persistent Net Losses
The company has consistently reported net losses, with a net income of $-72.21 million in 2024 and $-36.40 million in 2023, resulting in negative net margins (-121.1% and -72.5% respectively), indicating a lack of profitability.
Calendar
August 2025
5
Next Earnings Date
H: $-0.13
A: $-0.14
L: $-0.16
H: 12.60M
A: 12.17M
L: 11.67M
Profile
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices for use in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as process fingerprint data to support large-scale efforts in predictive bioprocess modeling. The company's products comprise Maven, an on-line device for bioprocess monitoring and control; Trace C2, an on-line monitoring of methanol or ethanol and control of substrate feeding in fermentation processes; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Seasonals
Price Target
6.50 USD
The 39 analysts offering 1 year price forecasts for MASS have a max estimate of 7.00 and a min estimate of 6.00.